Company profile

SK Biopharmaceuticals Co., Ltd.

326030 · KRX (KOSPI) (Two rows for one company. The epilepsy build resolved the sponsor string to a new row while 'SK Biopharmaceuticals Co., Ltd.' already existed from an earlier indication. Both are KOSPI 326030. Duplicate company row 1869 ("SK Biopharmaceuticals") merged into this one on 2026-08-06; source: https://www.skbp.com/eng/ir/stockInfo)

Public Market Listing

326030KRX (KOSPI)

KRX (KOSPI) primary exchange listing

Live quotes, historical charts, and market capitalization for SK Biopharmaceuticals Co., Ltd. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)

2Total Assets

1Approved

1Phase 3 / Filed

0Phase 1–2 / Early

1Diseases

Showing 2 of 2 assets

		Target & Modality
Cenobamate(Xcopri)	Approved	Voltage-gated sodium channelSmall molecule	Epilepsy
Carisbamate	Phase 3	Voltage-gated sodium channelSmall molecule	Epilepsy

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.